Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Investing.com - Raymond (NSE:RYMD) James maintained its Outperform rating and $9.00 price target on Compass Therapeutics (NASDAQ:CMPX) following the company’s second-quarter financial results and clinical trial updates. The clinical-stage biopharmaceutical company, currently valued at $373 million, has received strong analyst support with a consensus "Strong Buy" recommendation. According to InvestingPro data, analyst price targets range from $6 to $32 per share, suggesting significant potential upside.
Compass reported a net loss of $19.9 million and earnings per share of $(0.14) for the second quarter of 2025, slightly exceeding Raymond James’ projected loss of $18.6 million and EPS of $(0.13). The company ended the quarter with approximately $101 million in cash and equivalents, which management expects will provide runway into 2027. InvestingPro analysis highlights the company’s strong liquidity position with a current ratio of 8.33, indicating robust short-term financial health. While not currently profitable, Compass maintains minimal debt with a debt-to-equity ratio of just 0.06.
The biopharmaceutical company announced a timeline extension for its Phase 3 progression-free survival and overall survival results for tovecimig in combination with paclitaxel versus paclitaxel alone in second-line biliary tract cancer. These results are now expected in the first quarter of 2026, representing a delay from previous timelines.
Compass also disclosed initial data from its CTX-8371 (PD-1 x PD-L1) program, reporting two deep partial responses among 12 patients with prior PD-(L)1 inhibitor exposure, including one non-small cell lung cancer patient and one triple-negative breast cancer patient.
The company presented murine model data for CTX-10726 (PD-1 x VEGF-A) and announced plans for an Investigational New Drug (IND) submission during the fourth quarter of 2025.
In other recent news, Compass Therapeutics reported its second-quarter 2025 earnings, which did not meet analysts’ expectations. The company announced an earnings per share (EPS) of -$0.14, which was below the anticipated -$0.12, resulting in a 16.67% negative surprise. This earnings miss has raised concerns among investors, despite the company maintaining a strong cash position. The financial results have prompted discussions among analysts, although no specific upgrades or downgrades have been reported. These developments highlight the importance of closely monitoring Compass Therapeutics’ financial performance in the upcoming quarters. Investors are advised to keep an eye on future earnings reports to assess the company’s progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.